Serum Triglyceride Levels Research Articles

The Protective Effect of Boric Acid Against High Fructose-Induced Liver and Kidney Damage in Rats.

This study aimed to determine the protective role of boric acid (BA) in high fructose (HF)-induced liver and kidney toxicity in a young rat model. High-fructose consumption causes serious damage to liver and kidney tissue in healthy individuals and contributes to the emergence of various metabolic diseases. Thirty-two healthy female Wistar albino rats (250-300g weight and 3-4months) were randomly distributed into four equal groups (n = 8): control, high fructose % 20 (HF), boric acid 20mg/kg (BA), and HF + BA. High fructose was freshly prepared and administered to the rats as 20g of D-fructose dissolved in 100mL of tap water daily for a duration of 30days. Boric acid (20mg/kg) was administered through gastric gavage throughout the 30-day study period. At the end of study, blood, liver, and kidney were collected from rats. The results indicated that high fructose induced increased glucose, total cholesterol, triglyceride, and urea levels in rat serum. Boric acid administration significantly decreased glucose, total cholesterol, triglyceride, and urea levels in HF + BA groups. The results indicated that high fructose-induced oxidative stress by increasing the level of MDA and by decreasing GSH levels, and CAT activity in the liver and kidney of rats. However, oral BA administration significantly decreased MDA levels and increased GSH levels, and CAT activity (p < 0.05). Furthermore, BA significantly reduced high fructose-induced histopathological and Immunohistochemistry alteration in the liver and kidney tissues. In conclusion, BA may prevent the oxidative imbalance and histopathological and immunohistochemical damage caused by high fructose in liver and kidney tissues in rats.

Cholestyramine in hemodialysis: a new approach for hyperphosphatemia management.

Hyperphosphatemia is a potentially life altering condition in end-stage renal disease patients who are on regular hemodialysis that can lead to cardiovascular calcification, metabolic bone disease and secondary hyperparathyroidism. Bile acid sequestrants are anion exchange resins bind to bile acids and phosphate in the intestine resulting in preventing intestinal absorption of dietary phosphate, interruption of bile acid homeostasis and reduction in low-density lipoprotein cholesterol levels. Cholestyramine is chosen for study in hemodialysis patients based on the effectiveness and safety of bile acid sequestrants such colestilan and colestipol in the treatment of hyperphosphatemia and hypercholesterolemia in hemodialysis patients. A prospective, interventional, randomized, double blinded, placebo-controlled two arm study was carried out to assess the efficacy of oral cholestyramine on reduction of serum phosphate level in adult hemodialysis patients. 76 eligible patients were randomly assigned to either a drug group or a placebo group for the 2-month study period. The protocol was approved by the institutional review board of the faculty of pharmacy Ain Shams University Ethical committee and has been registered on ClinicalTrials.gov: NCT05577507. Over the 2-month treatment period, patients in cholestyramine group showed a significant decline in serum phosphorus levels versus placebo group (4.6 mg/dl vs. 6.6 mg/dl; p < 0.001) and serum calcium-phosphorus product (40 mg2/dl2 vs. 59.8 mg2/dl2; p < 0.001). Median serum triglyceride and low-density lipoprotein cholesterol levels had decreased significantly versus baseline values in the cholestyramine group. Cholestyramine used with phosphate binders effectively lowers phosphorus levels, improves the lipid profile, and has mild adverse effects.

OTUB1 mediates PARP1 deubiquitination to alleviate NAFLD by regulating HMGB1.

Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease characterized by hepatocyte steatosis, which excludes alcohol, drugs and other definite liver damage-related factors. It has been reported that OTUB1 serves a significant role in the regulation of glucose and lipid metabolism. The present study aimed to investigate the molecular mechanism underlying the effect of OTUB1 on regulating NAFLD. The NAFLD mouse model was induced via high-fat-diet, and glucose and insulin tolerance tests were then performed. In addition, the serum levels of total cholesterol (TC) and triglycerides (TG) were detected. The serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP) were assessed using the corresponding biochemical assays. Hematoxylin and eosin, and periodic acid-Schiff staining was carried out to evaluate the liver pathology in mice. The expression levels of the NAFLD-related genes and inflammatory genes were determined by reverse transcription-quantitative PCR, western blot analysis and immunofluorescence staining. Furthermore, the regulatory association between OTUB1 and poly (adenosine diphosphate-ribose) polymerase (PARP)-1 was assessed by co-immunoprecipitation assay. The results showed that OTUB1 was significantly upregulated in both in vitro and in vivo NAFLD models. Knockout of OTUB1 significantly improved affected glucose tolerance and insulin sensitivity, decreased TG and TC content, and decreased ALT, AST and ALP levels. In addition, the results show that OTUB1 can regulate the expression of PARP1 by inhibiting the ubiquitination of PARP1, while PARP1 knockout can inhibit liver inflammation by regulating HMGB1, thereby improving NAFLD. Targeting OTUB1 could be a potential therapeutic strategy for the NAFLD.

Chronic heat stress is capable of reducing the growth performance, causing damage to the liver structure, and altering the liver glucose metabolism and lipid metabolism in largemouth bass (Micropterus salmoides L.).

High temperatures cause abnormal energy metabolism and inhibit the growth of fish in aquaculture. However, the mechanism of energy metabolism under chronic heat stress is still unknown. In this study, largemouth bass (Micropterus salmoides, LMB) was treated with 25℃, 29℃, and 33℃ for 8weeks. Then, the growth performance, liver tissue damage, serum lipid indicator, hepatic glycogen, and triglyceride levels were analyzed. The growth data showed that the 33℃ group had a lower weight gain rate (WGR), specific growth rate (SGR), feeding rate (FR), and higher feed conversion rate (FCR) in comparison with those in the 25℃ and 29℃ groups. However, there were no significant differences between the 25℃ and 29℃ groups. The most severe damage to liver tissue was observed in the 33℃ group, characterized by cellular vacuolation and marginalization of cell nuclei. The levels of triglyceride, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in the serum were decreased with the rising temperatures. However, the hepatic triglyceride levels were increased, with a decrease in hepatic glycogen levels. Compared with the 25℃ group, the expressions of gluconeogenesis pathway-related genes (phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase (G6pase)) and glucose transport pathway-related gene (glucose transporter 2 (Gltu2)) were down-regulated in the 33℃ group. In contrast, the expression of the glycolysis pathway-related gene (pyruvate kinase (Pk)) was up-regulated. In addition, the expressions of fatty acid β oxidation pathway-related genes (peroxisome proliferator-activated receptor-Alpha (Pparα) and carnitine palmityl transferase 1 (Cpt1)), adipogenesis pathway-related genes (peroxisome proliferator-activated receptor-Gamma (Pparγ), fatty acid synthase (Fas), acetyl-CoA carboxylase (Acc)), and lipolysis pathway-related genes (adipose triglyceride lipase (Agtl) and hormone-sensitive lipase (Hsl)) were down-regulated under chronic heat stress. In conclusion, our results indicated that enhancement of the glycolysis pathway and inhibition of the gluconeogenesis pathway and lipid metabolism contribute to coping with chronic heat stress for LMB. Our study provides useful information for alleviating the heat stress response of LMB through nutritional regulation in the future.

Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial

Pemafibrate substantially lowers serum triglyceride (TG) levels and increases high-density lipoprotein cholesterol (HDL-C) levels primarily in Japan, but it has not been evaluated in China. We aimed to confirm the efficacy and safety of pemafibrate in Chinese patients with hypertriglyceridemia and low HDL-C levels by comparing placebo and fenofibrate. A multicenter, double-masked trial was conducted in China involving 344 patients with high TG and low HDL-C levels randomly assigned to one of four groups: pemafibrate 0.2 mg/d, pemafibrate 0.4 mg/d, fenofibrate 200 mg/d, or placebo for 12 weeks. The primary endpoint was the percentage change in fasting TG levels. The percentage change in TG levels from baseline was -34.1%, -44.0%, -30.5%, and 6.5% in the pemafibrate 0.2 mg/d, pemafibrate 0.4 mg/d, fenofibrate 200 mg/d, and placebo groups, respectively. Pemafibrate 0.4 mg/d significantly reduced TG levels compared with that in both placebo (p＜0.0001) and fenofibrate groups (p=0.0083). Significant improvements in HDL-C, remnant cholesterol, and apolipoprotein A1 levels were also observed with both doses of pemafibrate than with the placebo. Pemafibrate showed significantly smaller changes in alanine aminotransferase, aspartate aminotransferase, and serum creatinine levels than those with fenofibrate. In Chinese patients, pemafibrate exhibited superior efficacy in improving TG levels and enhanced hepatic and renal safety compared to fenofibrate. Thus, pemafibrate may represent a promising therapeutic option for dyslipidemia in Chinese patients.

Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial

BackgroundThe efficacy and mechanism of Fufang Danshen dripping pills (FFDS) in the secondary prevention of stable coronary heart disease (SCHD) is currently undetermined. This study aims to investigate the efficacy and preliminary mechanism by which FFDS may impact the progression of SCHD.MethodsBased on randomization, we administered oral FFDS to 30 patients with SCHD in addition to conventional treatment for 30 days. After treatment, three-months major adverse cardiovascular events (MACE) were assessed as the primary outcome. Additionally, we evaluated the patients' Seattle Angina Questionnaire score, blood pressure, circulating levels of total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, C-reactive protein, platelets, alanine aminotransferase, aspartate aminotransferase, serum creatinine, and fasting blood glucose as the secondary outcomes. Furthermore, we utilized mass spectrometry analysis, network pharmacology, and lipidomics to predict the potential mechanisms of FFDS in the treatment of SCHD.ResultsFollowing treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P = 0.013) and a reduction in the frequency of angina episodes (P = 0.021). We conducted mass spectrometry analysis on FFDS and identified 236 chemical components. Lipidomics further confirmed triglycerides as key lipids affected by FFDS. By integrating these findings with network pharmacology targets, we highlighted the potential roles of LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT in fat digestion, absorption, and metabolism pathways, suggesting their involvement in FFDS's treatment of SCHD by reducing triglycerides.ConclusionIn individuals with SCHD, the administration of FFDS has been shown to effectively reduce circulating triglyceride levels and decrease the frequency of angina episodes. This therapeutic effect is likely due to the active components of FFDS targeting key proteins: LPL, CD36, FABPpm, L-FABP, LCAT, and CEPT.Clinical Trial Registrationhttps://www.chictr.org.cn/, identifier (ChiCTR2400080149).

Mechanisms of combined deer antler polysaccharides and postbiotics supplementation for regulating obesity in mice

Objective: This study investigated the mechanisms related to lipid metabolism regulation after combined supplementation with deer antler polysaccharides and postbiotics. Methods: Thirty-two male mice were divided into high-fat diet, HD + deer antler polysaccharides, HD + Bacillus coagulans postbiotics, and HD + deer antler polysaccharides + B. coagulans postbiotics groups. The diets contained 60% fat. After 9 weeks, the effects of deer antler polysaccharides and postbiotics on lipid metabolism were assessed through blood biochemical, histological tissue staining, and polymerase chain reaction analyses. Results: Supplementation with deer antler polysaccharides and postbiotics significantly inhibited weight gain in obese mice, reduced serum total cholesterol, triglyceride, and low-density lipoprotein levels and markedly increased the serum high-density lipoprotein level. Additionally, hepatic lipid droplet accumulation and adipocyte hypertrophy improved. The expressions of the lipid synthesis genes, sterol regulatory element-binding protein 1 (i.e. SREBP-1c), and fatty acid synthase (i.e. FAS), significantly decreased, while peroxisome proliferator-activated receptor alpha (i.e. PPAR-α) and acyl-CoA oxidase 1 (i.e. ACOX1) expression significantly increased. The expressions of the inflammation-related genes, tumor necrosis factor-alpha (i.e. TNF-α), interleukin (IL)-6, and IL-1 also significantly decreased. Conclusion: Thus, combined deer antler polysaccharides and postbiotic supplementation regulated obesity in mice, potentially by modulating lipid synthesis and inflammation-related gene expression.

Understanding Lipid Abnormalities in Schizophrenia: A Review of Cholesterol and Triglyceride Levels Pre- and Post-Treatment

Schizophrenia is a complicated mental condition that profoundly impairs cognitive and behavioral abilities, frequently disrupting everyday living and leading to poor health outcomes. Among the many health concerns connected with schizophrenia, lipid metabolic abnormalities, particularly in total cholesterol and serum triglyceride levels, have received attention due to their impact on cardiovascular health. This literature review examines the link between schizophrenia and lipid profiles, with an emphasis on drug-naive patients, those receiving antipsychotic medication, and first-degree relatives. This review, which synthesizes findings from several studies, highlights the impact of antipsychotic medicines on lipid levels, identifies potential biomarkers for schizophrenia, and emphasizes the importance of monitoring lipid metabolism in patients. It also looks at the historical context of lipid abnormalities in schizophrenia, including early observations and current research relating metabolic changes to the disorder's etiology. The review continues by exploring the therapeutic significance of these findings, emphasizing the need for integrated care approaches that address both mental and metabolic health in schizophrenia patients. Keywords: Schizophrenia, Lipid Metabolism, Total Cholesterol, Serum Triglycerides, Antipsychotic Treatment

The Association Between Metabolic Syndrome and the Risk of Endometrial Cancer in Pre- and Post-Menopausal Women: A UK Biobank Study

Background: Metabolic syndrome (MetS) is a syndrome that comprises central obesity, increased serum triglyceride (TG) levels, decreased serum HDL cholesterol (HDL) levels, raised blood pressure (BP), and impaired glucose regulation, including prediabetic and diabetic glycaemic levels. Recently, the association with endometrial cancer (EC) has been described but it is unclear if the risk associated with MetS is higher than the individual effect of obesity alone. This study investigates the association between MetS components and differing MetS definitions on EC risk and compares the risk of MetS with the risk posed by obesity alone. It also analyses how MetS affects the risk of EC development in the pre- and post-menopausal subgroups. Methods: A prospective cohort study was undertaken using data from the UK biobank. Multivariable Cox proportional risk models with the time to diagnosis (years) were used to estimate the hazard ratio (HR) and 95% confidence interval (CI) of MetS and its components on the risk of EC. A subgroup analysis was also undertaken for pre- and post-menopausal participants. Kaplan–Meier (KM) was undertaken to assess the difference in the risk of EC development in differing BMI classes, and in pre- and post-menopausal subgroups. Results: A total of 177,005 females from the UK biobank were included in this study. Of those participants who developed EC (n = 1454), waist circumference &gt; 80 cm, BMI &gt; 30 kg/m2, hypertension &gt; 130/80 mmHg, hyperlipidaemia and diabetes (HbA1C &gt; 48 mmol/L were significant predictors of EC development, with waist circumference being the strongest predictor (HR = 2.21; 95% CI: 1.98–2.47, p &lt; 0.001). Comparing the pre- and post-menopausal subgroup, hypertriglyceridaemia and diabetes were the strongest predictors of EC in the pre-menopausal subgroup (HR = 1.53; 95% CI: 1.18–1.99 and HR = 1.51; 95% CI: 1.08–2.12, p &lt; 0.05, respectively). Raised waist circumference was not a significant independent predictor in the pre-menopausal subgroup. A KM curve analysis showed a clear distinction between those with and without MetS in the pre-menopausal group, suggesting a benefit of testing for MetS components in pre-menopausal women with obesity. Conclusions: Components of MetS, both independently and in combination, significantly increase the risk of EC. Screening those with obesity for MetS in their pre-menopausal years may help to identify those at the highest risk.

Timosaponin B II as a novel KEAP1-NRF2 inhibitor to alleviate alcoholic liver disease:Receptor structure-based virtual screening and biological evaluation.

Oxidative stress induced by excess ethanol is an important factor in the progression of alcoholic liver disease (ALD). In recent years, inhibiting Kelch-like ECH-associated protein 1 (KEAP1) to activate the antioxidant regulator Nuclear factor erythroid 2-related factor 2 (NRF2) has been considered an effective strategy for treating oxidative stress-related diseases, but its application in ALD remains insufficiently explored. This study aims to discover high-affinity inhibitors targeting the KEAP1 receptor. We conducted virtual screening of a compound library based on a structure-based pharmacophore model, ultimately identifying the candidate compound Timosaponin B II (TBII). Subsequently, we established ALD models in AML-12 cells and C57BL/6 mice, and evaluated the therapeutic effects and mechanisms of TBII on ALD using methods including Immunofluorescence, Western blotting, RT-qPCR, Biochemical assays, and histological staining. Results indicate that TBII significantly improved ethanol-induced liver injury, inhibited the elevation of serum Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Total Cholesterol (T-CHO), and Triglycerides (TG) levels, and reduced lipid droplet accumulation in liver tissues. Furthermore, TBII treatment enhanced the antioxidant capacity of AML-12 cells and mouse liver, increasing Glutathione (GSH) and Superoxide Dismutase (SOD) levels while reducing Malondialdehyde (MDA) and Reactive Oxygen Species (ROS) levels. Mechanistic studies indicated that TBII inhibited the ethanol-induced increase in KEAP1 and reversed the ethanol-induced changes in NRF2 and its downstream targets. In conclusion, this study suggests that TBII may become a potential therapeutic agent for ALD by modulating the KEAP1-NRF2 pathway to alleviate oxidative stress and lipid metabolism abnormalities.

Triglyceride lowering in patients with different severities of hypertriglyceridaemia-associated acute pancreatitis: secondary analysis of a multicentre, prospective cohort study

ObjectiveIt is controversial whether rapid lowering of triglyceride (TG) levels is associated with clinical benefits in patients with hypertriglyceridaemia-associated acute pancreatitis (HTG-AP). In particular, patients with different severity of disease...

Ferula (Ferula elaeochytris) as a phytoestrogen: Use of Ferula in laying hens.

This study aims to examine the effects of Ferula root powder (FRP) on performance, egg quality, egg oxidant/antioxidant levels, some serum hormone/biochemical parameters, and physical properties of the oviduct in laying hens. A total of 72 (8 replicates, 3 hens/subgroup) laying hens (Nick Brown, 30 weeks) were divided into three groups (FRP-0, FRP-1, FRP-2). During the 9-week trial, FRP-0 (control) was fed with a basal diet (16.88% crude protein, 2,725 kcal/kg metabolizable energy). FRP-1 and FRP-2 groups, however, were fed a diet supplemented with 1 g/kg and 2 g/kg FRP, respectively. The results showed that laying performance, serum hormone (estradiol, progesterone) levels, and some internal organ weights were not affected by FRP supplementation. In comparison to the control group, higher yolk height and yolk index were found in the FRP-added groups. The albumen pH was found to have decreased in FRP-2 group. DPPH radical scavenging activity increased in egg yolk. TBARs value decreased in FRP-1 and FRP-2 groups. Serum triglyceride and cholesterol levels decreased in group FRP-2. Moreover, a higher uterus length was found in the FRP-supplemented group. Given the results achieved, it was determined that FRP does not have a significant estrogenic effect. However, FRP can be utilized to prevent lipid oxidation and for its hypocholesterolemic effect.

Application of fourier transform infrared vibrational spectroscopy in identifying early biochemical changes in lipid profiles of individuals undergoing Roux-en-y gastric bypass

BackgroundFourier transform infrared spectroscopy (FTIR) is an analytical technique increasingly applied in biological analysis. This study investigates the application of FTIR to identify early biochemical changes, particularly in lipid profiles, in individuals undergoing Roux-en-Y gastric bypass (RYGB).MethodsAn observational study involving patients from a university hospital’s Bariatric and Metabolic Surgery Program, with evaluations performed before (T0) and two months after (T1) RYGB. Biochemical parameters, anthropometric data, and body composition were assessed. FTIR spectra were pre-processed and analyzed using Principal Component Analysis and Partial Least Squares Discriminant Analysis. The normality of the data was evaluated using the Kolmogorov-Smirnov test, followed by paired T-tests or Wilcoxon tests as appropriate. Spearman correlation analysis of spectral information with biochemical parameters was also performed. A significance level of p < 0.05 was set for all tests. The university hospital’s Research Ethics Committee approved the study (protocol CAAE 59075722.7.0000.5071).ResultsThe study evaluated 29 individuals (86.2% female) with a mean age of 41.2 ± 7.8 years. Significant differences were observed in anthropometric parameters and body composition (p < 0.001). Additionally, early improvements in the lipid profile were noted, with significant decreases in triglycerides, total cholesterol, and LDL cholesterol (p < 0.05) just two months post-surgery. FTIR identified correlations between biochemical parameters and specific spectral regions at T0 and T1. Notably, serum triglycerides showed a significant correlation with the lipid-specific spectral region (1796–1685 cm− 1) at both time points (p < 0.05).ConclusionFTIR can effectively monitor biochemical changes in RYGB surgery patients. The spectral range associated with lipid functional groups (1796 –1675 cm⁻¹) showed a significant relationship with serum triglyceride levels before and after RYGB. Additionally, various biochemical parameters exhibited strong correlations with other spectral regions, implying that the serum spectral profile can indicate biochemical variations at different post-surgery stages.Trial registrationBrazilian Registry of Clinical Trials (Rebec), September 5, 2022, protocol RBR-26chs2g.

Nucleotide sequence variants, gene expression and serum profile of immune and antioxidant markers associated with brucellosis resistance/susceptibility in Shami goat

Brucellosis is a highly contagious zoonotic bacterial disease. It has considerable negative consequences on the animal production industry worldwide. The objective of this study was to investigate the genetic and molecular variations in Shami goat susceptible to Brucella infection. Blood samples were collected from fifty mature Shami goats (30 Brucella-infected does and 20 non-infection). DNA was extracted and selected parts the immunity; solute carrier family 11 member 1 (SLC11A1), toll-like receptor 1 (TLR1), toll-like receptor 9 (TLR9), SP110 nuclear body protein (SP110), the adenosine A3 receptor (ADORA3), caspase activating recruitment domain 15 (CARD15) and interferon regulatory factor 3 (IRF3), antioxidant glutathione peroxidase 1 (GPX1), nitric oxide synthase (NOS), NAD(P)H dehydrogenase [quinone] 1 (NQO1) and transcription factor NF-E2-related factor 2 (Nrf2) and erythritol related transketolase (TKT), ribose 5-phosphate isomerase (RPIA) and Adenosine monophosphate deaminase (AMPD) genes were sequenced. Likewise, the levels of gene expressions were investigated. The results identified polymorphic variants between healthy and infected does. Levels of gene expression of SLC11A1, TLR1, TLR9, SP110, ADORA3, CARD15, IRF3, HMOX1, TKT, RPIA and AMPD were significantly (P < 0.05) up regulated in the infected compared to the non-infected ones. On the other hand, GPX1, NOS, NQO1 and Nrf2 genes were significantly (P < 0.05) downregulated in the infected compared to the non-infected does. The results of serum profile indicated that there is a significant (P < 0.05) increase in the activities of AST, ALT, GGT, LDH, ALP as well as serum level of globulin, triglycerides, cholesterol, MDA, NO, IL-1β, TNF-α, IgM, IgG, haptoglobin and amyloid A. On the other hand, there were significant reductions in the glucose, total protein albumin, urea, calcium, inorganic phosphorus, sodium, copper, zinc, iron, TAC, GSH, SOD, GPx, IL-10 and fibrinogen in the infected compared to the non-infected does. Our results provide valuable information about the serum profile variations and putative genetic markers for Brucella infection in goats. This could be utilized in controlling goat brucellosis through selective breeding of natural resistant animals.

Effects of Enterococcus faecalis Supplementation on Growth Performance, Hepatic Lipid Metabolism, and mRNA Expression of Lipid Metabolism Genes and Intestinal Flora in Geese.

The effects of Enterococcus faecalis (E. faecalis) at a concentration of 1.0 × 108 CFU/mL on growth performance, hepatic lipid metabolism, and mRNA expression related to lipid metabolism, intestinal morphology, and intestinal flora were investigated in geese. A total of 60 male geese, aged 30 days and of similar weight, were randomly assigned to 2 groups. Each group was divided into six replicates, with five geese per replicate. During the 45-day experiment, the control group received a basal diet, while the experimental group was provided with the same basal diet supplemented with E. faecalis in drinking water at a concentration of 1.0 × 108 CFU/mL. E. faecalis significantly increased the half-eviscerated weight of geese and improved ileal intestinal morphology (p < 0.05). Serum triglyceride (TG) levels were significantly reduced on day 5, while serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels were significantly decreased on day 25 (p < 0.05). By day 45, serum TG and free fatty acid (FFA) levels were also significantly reduced (p < 0.05). Additionally, E. faecalis significantly increased the HDL/LDL ratio and serum high-density lipoprotein cholesterol (HDL-C) levels (p < 0.05). Serum insulin levels were significantly elevated on day 25, and glucagon-like peptide-1 (GLP-1) levels were significantly increased on day 45 (p < 0.05). On day 25 of the trial, hepatic TG levels, FFA levels, and Oil Red O-stained areas in the liver were significantly reduced (p < 0.05), accompanied by significantly decreased mRNA expression of hepatic acetyl-CoA carboxylase (ACCA) (p < 0.05). Conversely, the mRNA expression levels of fatty acid synthase (FASN), farnesoid X receptor (FXR), sterol regulatory element-binding protein 1 (SREBP-1), and peroxisome proliferator-activated receptor-α (PPARα) were significantly elevated (p < 0.05). A 16S rRNA diversity analysis of ileal contents on day 25 revealed significant differences in intestinal flora composition between the control and E. faecalis groups. The 16S rRNA data demonstrated a strong correlation between microbial communities and lipid-related physiological and biochemical indicators (p < 0.05). In conclusion, E. faecalis supplementation promoted fatty acid oxidation, reduced blood lipid levels, alleviated hepatic lipid accumulation, and improved ileal morphology and intestinal flora diversity, thereby enhancing growth performance and lipid metabolism in geese. These findings suggest that E. faecalis is a promising probiotic candidate for development as a feed additive.

Clinical Outcomes in A Multi-center Cohort Involving 919 Patients with Hypertriglyceridemia-associated Acute Pancreatitis.

Hypertriglyceridemia-associated acute pancreatitis (HTG-AP) is one of the most common etiologies of acute pancreatitis (AP) worldwide. Compared to other etiologies, patients with HTG-AP may develop more severe AP, but previous studies yielded controversial conclusion due to the lack of adequate adjustment for the confounders. Therefore, this study aimed to examine the possibility and risk factors of developing severe AP in HTG-AP. Data from patients with an established diagnosis of AP were collected from January 2013 to December 2023 using a pre-designed data collection form and were gathered from five tertiary cross-regional centers of China. HTG-AP was defined as serum triglyceride (TG) levels >500 mg/dl and excluded other etiologies. The possibility and risk factors of severe AP were assessed by multivariable logistic regressions after adjusting potential confounders. A prediction model was established and validated. Between 2013 to 2023, we identified a total of 6996 patients with AP, of whom 4378 were included in the final analysis. Compared to other etiologies, patients with HTG-AP had a higher risk of developing severe AP (odds ratio [OR]: 1.897; 95% confidence interval [CI]: 1.380-2.608; p<0.001) and organ failure. HTG-AP patients showed higher possibility for developing respiratory and circulation failure but renal failure compare to other etiologies. In HTG-AP patients, risk factors for severe AP included age, fasting blood glucose, white blood cell (WBC) counts, and the presence of pleural effusion. Triglyceride level was found not significantly associated with severity in HTG-AP patients. A prediction model incorporating these risk factors demonstrated an AUC of 0.837 in the training and 0.883 in the testing set, with adequate calibration. Using a multi-center cross-regional cohort, we demonstrated that HTG-AP had a higher risk of developing severe AP and organ failure. A risk prediction model for predicting severe AP was developed and effectively stratified patients.

Beneficial Effect of Fenofibrate in Combination with Silymarin on Parameters of Hereditary Hypertriglyceridemia-Induced Disorders in an Animal Model of Metabolic Syndrome.

Background: Hypertriglyceridemia has serious health risks such as cardiovascular disease, type 2 diabetes mellitus, nephropathy, and others. Fenofibrate is an effective hypolipidemic drug, but its benefits for ameliorating disorders associated with hypertriglyceridemia failed to be proven in clinical trials. Methods: To search for possible causes of this situation and possibilities of their favorable influence, we tested the effect of FF monotherapy and the combination of fenofibrate with silymarin on metabolic disorders in a unique model of hereditary hypertriglyceridemic rats (HHTg). Results: Fenofibrate treatment (100 mg/kg BW/day for four weeks) significantly decreased serum levels of triglyceride, (-77%) and free fatty acids (-29%), the hepatic accumulation of triglycerides, and the expression of genes encoding transcription factors involved in lipid metabolism (Srebf2, Nr1h4. Rxrα, and Slco1a1). In contrast, the hypertriglyceridemia-induced ectopic storage of lipids in muscles, the heart, and kidneys reduced glucose utilization in muscles and was not affected. In addition, fenofibrate reduced the activity of the antioxidant system, including Nrf2 expression (-35%) and increased lipoperoxidation in the liver and, to a lesser extent, in the kidneys and heart. Adding silymarin (micronized form, 600 mg/kg BW/day) to fenofibrate therapy increased the synthesis of glycogen in muscles, (+36%) and reduced hyperinsulinemia (-34%). In the liver, it increased the activity of the antioxidant system, including PON-1 activity and Nrf2 expression, and reduced the formation of lipoperoxides. The beneficial effect of combination therapy on the parameters of oxidative stress and lipoperoxidation was also observed, to a lesser extent, in the heart and kidneys. Conclusions: Our results suggest the potential beneficial use of the combination of FF with SLM in the treatment of hypertriglyceridemia-induced metabolic disorders.

Lipid levels and insulin resistance markers in patients with colorectal cancer: Propensity score matching analysis.

Colorectal cancer (CRC) is a prevalent malignant neoplasm characterized by subtle early manifestations. To investigate the correlation among serum lipid profiles, the triglyceride-glucose (TyG) index, and the atherosclerotic index (AI) in patients with CRC. Furthermore, it explored the clinical diagnostic utility of combining serum lipids with cancer antigens in the context of CRC. A retrospective analysis encompassed 277 patients with CRC and 1034 healthy individuals. Following propensity score matching, patients with CRC exhibited significantly reduced levels of serum triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol (LDL-C), as well as a diminished TyG index. Conversely, they displayed elevated AI levels compared to their healthy counterparts. Patients in advanced stages exhibited lower serum levels of TG, TC, and LDL-C compared to those in early stages. Patients with positive lymph node metastasis demonstrated reduced levels of TG, LDL-C, and the TyG index. Receiver operating characteristic analysis revealed that the combination of the TyG index, carcinoembryonic antigen, and carbohydrate antigen 19-9 yielded the highest positive prediction rate for CRC at 75.3%. Preoperative serum lipid profiles exhibit a robust association with patients with CRC. The concurrent assessment of multiple serum lipids and cancer antigens effectively enhances the diagnostic accuracy for CRC.

Clinical Value of Renal Function Markers Combined with Blood Lipid Levels during Late Pregnancy to Predict Preeclampsia: A Retrospective Case-Control Study

Background: Preeclampsia (PE) is a common complication of pregnancy and there is currently a lack of valuable diagnostic and predictive methods for it. This study aimed to explore the association between renal function markers, blood lipid levels in late pregnancy and PE, then assess the combined predictive value for PE. Methods: This was a retrospective case-control study that selected 263 eligible patients in late pregnancy diagnosed with PE as the case group and 264 healthy parturients as the control group. All participants were hospitalized from January 2021 to December 2023. The levels of serum renal function [creatinine (Cr), uric acid (UA) and urea] and blood lipid [total cholesterol (TC), triglycerides (TG) and high-density lipoprotein (HDL)] were compared between two groups. Logistic regression analysis was used to explore the association between these indicators and PE. Then the receiver operating characteristic (ROC) curve was drawn to evaluate the predictive value of them for PE. p &lt; 0.05 was considered statistically significant. Results: Univariate analysis showed that the PE group had significantly higher levels of TG, Cr, UA, and urea than the control group [3.56 (3.01–4.38) mmol/L vs. 2.98 (2.50–3.42) mmol/L, 54.00 (47.00–62.00) μmol/L vs. 46.00 (42.00–51.00) μmol/L, 367.00 (305.50–425.00) μmol/L vs. 278.00 (244.00–306.00) μmol/L, 3.50 (2.75–4.40) mmol/L vs. 2.90 (2.60–3.55) mmol/L respectively]. Multivariable analysis showed that the serum TG [adjusted odds ratio (AOR) = 1.827 (95% confidence interval (95% CI) = 1.277–2.615)], Cr [AOR = 1.066 (95% CI = 1.028–1.106)] and UA [AOR = 1.016 (95% CI = 1.011–1.022)] were risk factors for PE (p &lt; 0.001). ROC curves revealed that areas under the curve (AUC) were 0.703 (95% CI = 0.658–0.747), 0.734 (95% CI = 0.691–0.777) and 0.822 (95% CI = 0.786–0.857) respectively. The AUC, sensitivity and specificity of the combination of TG, Cr and UA were 0.864 (95% CI = 0.833–0.896), 76.4%, and 84.8%. Conclusions: The increased levels of serum TG, Cr and UA imply greater possibility of PE, thus they are considered as the risk factors. And their combination has a certain predictive value for PE, which may offer a fresh, convenient and efficient method for the diagnosis and treatment of PE.

Submicron Dispersions of Phytosterols Reverse Liver Steatosis with Higher Efficacy than Phytosterol Esters in a Diet Induced-Fatty Liver Murine Model.

Consumption of phytosterols is a nutritional strategy employed to reduce cholesterol absorption, but recent research shows that their biological activity might go beyond cholesterol reduction for the treatment of metabolic dysfunction-associated fatty liver disease (MAFLD), and novel phytosterol formulations, such as submicron dispersions, could improve these effects. We explored the therapeutic activity of phytosterols, either formulated as submicron dispersions of phytosterols (SDPs) or conventional phytosterol esters (PEs), in a mouse model of MAFLD. MAFLD was induced in mice by atherogenic diet (AD) feeding. The reversion of distorted serum and liver parameter values after a period of AD feeding was investigated after supplementation of the AD with SDPs, PEs, or a placebo (PT). Additionally, the metabolic parameters of fatty acid synthesis, fatty acid oxidation, and inflammation were studied to understand the mechanism of action of phytosterols. AD supplementation with SDPs was shown to reduce liver fat, along with showing a significant improvement in liver triglycerides (TGs), free fatty acids (FFAs), and liver cholesterol levels. These results were reinforced by the analyses of the liver steatosis scores, and liver histologies, where SDP intervention showed a consistent improvement. Treatment with PEs showed slighter effects in the same analyses, and no effects were observed with the PT treatment. Additionally, SDP intervention reversed, with a higher efficacy than PEs, the effect of AD on the serum levels of TGs, total- and LDL-cholesterol levels, and glucose levels. And, exceptionally, while SDP improved HDL-cholesterol serum levels, PEs did not show any effect on this parameter. We provide evidence for the therapeutical activity of phytosterols in MAFLD beyond the regulation of cholesterol levels, which is increased when the phytosterols are formulated as submicron dispersions compared to ester formulations.